Pharma Sector Sees Bearish Sentiment on September 22
The pharmaceutical sector is experiencing strong bearish positions on September 22, with Glenmark, Cipla, Alkem, and Dr Reddy’s seeing short positions.
Sacchitanand Uttekar, Vice President of Research and Data Analysis at Tradebulls Securities, attributes the bearish sentiment to profit-booking pressure. He points to Cipla, which recently broke below a crucial support level of Rs 1,230, as a sign of potential weakness in the stock.
Options data indicates that call writers are dominant for the day, with heavy call writing at the 1200 strike price for Cipla options, forming key resistance. As a derivative strategy, Uttekar recommends traders initiate fresh short positions in Cipla with a suggested stop loss of around Rs 1,228 to manage risk. He anticipates an intraday swing toward Rs 1,185 on the lower side with an ultimate positional target for Cipla at around Rs 1,170.
Glenmark Pharma also led the selling spree on September 22, after the company announced that it would sell a 75 percent stake in subsidiary Glenmark Life Sciences Ltd to Nirma Ltd for Rs 5,652 crore at Rs 615 per share.
Options data highlights the Rs 800 strike price as the key resistance level for the day, as it witnesses call writers initiating positions at this particular level.
September Series Pharma Sectoral Outlook
Rajesh Palviya, Senior Vice-President of Research and Head of Technical Derivatives at Axis Securities, said that the Nifty Pharma Index had witnessed profit booking near the 15,700-15,750 levels in August expiry with a decrease in open interest indicating Long unwinding, while in the current September series also 15700 acted as a stiff resistance.
Palviya believes that the 14700-14800 levels form an important support zone and any sustained move below the same will indicate further weakness.
“Sectoral OI has increased by 18 percent with Stocks like Granules and Auropharma seeing long built up and Cipla, Zydus Lifesciences & Lauras Labs have witnessing short built up in current series,” Palviya added. He highlights significant volume activity witnessed in Alkem, Aurobindo Pharma, Lupin and granules.
Aurobindo Pharma has a high OI concentration in call of 900 strike indicating strong resistance for this expiry while on the put side it’s at 850 and 860 strike, which is likely to act as strong support. Along with high OI concentration, there has also been writing on the put side at 850 strike further cementing the bullish view in the stock. Palviya suggests traders initiate a moderately bullish strategy called BULL CALL SPREAD.
For the September 28 expiry, Palviya recommends traders buy one lot of 870 call strike at Rs 12.50 and simultaneously sell one lot of 900 call strike at Rs 4 so that net outflow or maximum loss will be restricted to up to Rs 9,350.
“Auropharma on expiry if closes above 879 the strategy will start making a profit, however, the maximum gains will be restricted up to Rs 23,600 only because the gains of long 870 strike call will be offset by the sold 900 strike call if Auropharma closes above 900 on expiry,” added Palviya.
Overall, the pharmaceutical sector is seeing bearish sentiment on September 22, with profit-booking pressure and short positions in several individual stocks. Traders should be cautious and monitor the market closely for any further developments.
- 22 Sep
Technical Analysis Report for Nifty and Three Buy Calls
The Nifty index has been on a strong uptrend in the past three weeks, but it has recently retraced some of those gains. It is now expected to oscillate within the 19,605 to 19,878 range over the next few sessions. Three stocks that look good for buying over the next 2-3 weeks are Havells India, KSB, and Gujarat Ambuja Exports. All three stocks have strong bullish momentum and are trading above their key moving averages.
- 22 Sep
Maruti Suzuki Stock Gains on Bullish Stance from Global Brokerages
Maruti Suzuki stock gains on bullish stance from global brokerages Shares of Maruti Suzuki India surged on Friday after global brokerages Citi and Morgan Stanley maintained bullish stance on the counter. Both brokerages cited the company's improving product mix and attractive valuation as key reasons for their optimism. In addition, Maruti Suzuki reported strong sales performance in August 2023, with total domestic sales jumping 14 percent year-on-year and sale of utility vehicles jumping 118 percent year-on-year. Overall, the bullish stance from global brokerages and the company's strong sales performance are providing a boost to Maruti Suzuki stock.
- 22 Sep
PNB Gilts Hits Upper Circuit on Inclusion of Indian Bonds in JPMorgan Index
Shares of PNB Gilts hit upper circuit on September 22, 2023, following news that India's inclusion in JPMorgan's bond index is seen driving billions of dollars of inflows. The index provider will add Indian bonds to its widely-tracked emerging market index starting June 28, 2024. PNB Gilts is a primary dealer in government securities and other fixed-income instruments. The inclusion of Indian bonds in JPMorgan's index is expected to attract significant foreign inflows, which is likely to benefit PNB Gilts and other primary dealers in government securities.
- 22 Sep
Indian Bond Markets to Remain Stable in Near Term After JPMorgan Inclusion
Indian bond markets are expected to remain stable in the near term after JPMorgan's inclusion of India in its widely tracked emerging market debt index, according to BlackRock's head of Asia Pacific fixed income, Neeraj Seth. Seth expects inflows of around $20 billion to $25 billion into India after the maximum weight threshold is achieved on the GBI-EM index. Given the size of the global government bond market, this is relatively small and is unlikely to have a significant impact on volatility.
- 22 Sep
Indian market drops on September 22 despite inclusion of Indian bonds in JP Morgan index
Indian benchmark indices Sensex and Nifty fell for the fourth consecutive day on September 22, despite the inclusion of Indian bonds in the JP Morgan Government Bond Index-Emerging Markets (GBI-EM) global index suite from June 2024. The market is expected to remain volatile in the near term, with key support at 19,600 for Nifty.